236 related articles for article (PubMed ID: 11959617)
1. In vitro activity of linezolid against Clostridium difficile.
Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
3. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
5. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
[TBL] [Abstract][Full Text] [Related]
9. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Leroi MJ; Siarakas S; Gottlieb T
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510
[No Abstract] [Full Text] [Related]
10. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
[TBL] [Abstract][Full Text] [Related]
11. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Caspers P; Bruyère T; Schroeder S; Pfaff P; Knezevic A; Keck W; Ritz D
Antimicrob Agents Chemother; 2014; 58(2):901-8. PubMed ID: 24277035
[TBL] [Abstract][Full Text] [Related]
12.
Freeman J; Pilling S; Vernon J; Wilcox MH
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993853
[TBL] [Abstract][Full Text] [Related]
13. Failure of intravenous linezolid to treat Clostridium difficile associated diarrhea.
Lazzarini L; De Lalla F
J Chemother; 2003 Jun; 15(3):299-300. PubMed ID: 12868561
[No Abstract] [Full Text] [Related]
14. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL
J Chemother; 2003 Apr; 15(2):113-7. PubMed ID: 12797385
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance and Clostridium difficile, Germany.
Zaiss NH; Witte W; Nübel U
Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Hecht DW; Galang MA; Sambol SP; Osmolski JR; Johnson S; Gerding DN
Antimicrob Agents Chemother; 2007 Aug; 51(8):2716-9. PubMed ID: 17517836
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
20. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]